Internship

Medical Office Operations Intern

Confirmed live in the last 24 hours

Click Therapeutics

Click Therapeutics

51-200 employees

Develops software as prescription medical treatments

Biotechnology
Healthcare

Compensation Overview

$22Hourly

New York, NY, USA

This is a hybrid internship requiring in-office attendance on Wednesdays and Fridays.

Category
Healthcare Administration & Support
Medical, Clinical & Veterinary
Required Skills
Data Analysis

You match the following Click Therapeutics's candidate preferences

Employers are more likely to interview you if you match these preferences:

Degree
Experience
Requirements
  • Rising Sophomore or Junior currently pursuing an undergraduate degree in Health Sciences, Biomedical/Biochemistry, Public Health, or Healthcare Administration
  • Excellent interpersonal, teamwork, and collaboration skills
  • Attention to detail and organizational skills, and demonstrates professional work ethic
  • Google Suite or Microsoft Office
  • Good written and verbal communication skills
  • Hands-on experience acquired through internships, jobs, research, or personal projects
Responsibilities
  • Medical Operations and Strategy: creating meeting decks and tracking budgets
  • Clinical Operations: Assist with protocol review and data management
  • Clinical Science: Assist with research projects
  • Medical Affairs: Support identifying and engaging with leading experts in relevant therapeutic areas
  • Biostatistics: Collaborate with teams responsible for data analysis and interpretation
  • Support additional special projects on an Ad-hoc basis
Desired Qualifications
  • Experience working in biotechnology or clinical research
  • Experience with AI Systems such as Gemini
  • Experience utilizing google sheets, data systems

Click Therapeutics develops software applications that function as prescription medical treatments for patients with various health conditions. These digital therapeutics are designed to change cognitive and neurobehavioral mechanisms related to diseases, and they are tested through rigorous randomized controlled trials to ensure safety and effectiveness. After validation, the company seeks FDA clearance to market these applications as class II medical devices. Unlike traditional pharmaceuticals, Click Therapeutics' products are prescribed by physicians and reimbursed by payers, allowing for a unique revenue model. Their collaboration with Boehringer Ingelheim highlights their commitment to advancing digital therapeutics, particularly in treating conditions like schizophrenia. The goal of Click Therapeutics is to provide effective digital solutions for patients with unmet medical needs, continuously improving their applications using real-world evidence.

Company Size

51-200

Company Stage

Debt Financing

Total Funding

$93.9M

Headquarters

New York City, New York

Founded

2012

Simplify Jobs

Simplify's Take

What believers are saying

  • FDA clearance of Rejoyn™ boosts credibility in digital therapeutics for mental health.
  • Acquisition of Better Therapeutics expands Click's portfolio in cardiometabolic diseases.
  • $20 million financing from HSBC supports accelerated development and commercialization.

What critics are saying

  • Increased competition in digital therapeutics could impact Click's market share.
  • Rapid technological advancements may strain resources for software updates.
  • Integration challenges from Better Therapeutics acquisition could disrupt operations.

What makes Click Therapeutics unique

  • Click Therapeutics develops software as medical treatments for unmet medical needs.
  • Their Clickometrics® platform personalizes user experience to optimize engagement and outcomes.
  • Partnerships with Boehringer Ingelheim and Otsuka enhance their digital therapeutic offerings.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

Life Insurance

401(k) Company Match

Unlimited Paid Time Off

Flexible Work Arrangement

Stock Options

Performance Bonus

Fertility Treatment Support

Professional Development Budget

Commuter Benefits

Growth & Insights and Company News

Headcount

6 month growth

2%

1 year growth

4%

2 year growth

5%
The Healthcare Technology Report
Nov 28th, 2024
Click Therapeutics Launches Software-Enhanced Drug Therapies

Click Therapeutics launches Software-Enhanced Drug therapies.

Business Wire
Oct 8th, 2024
Click Therapeutics Founder and CEO David Benshoof Klein Named to 2024 PharmaVoice 100 List

NEW YORK-(BUSINESS WIRE)-David Benshoof Klein, founder and chief executive officer of Click Therapeutics, has been honored as a PharmaVoice 100 winner.

Business Wire
Aug 13th, 2024
Otsuka Precision Health and Click Therapeutics Announce Launch of Rejoyn(TM), the First-And-Only Prescription Digital Therapeutic Cleared by the FDA for the Adjunctive Treatment of Major Depressive Disorder (MDD) Symptoms

PRINCETON, N.J. & NEW YORK-(BUSINESS WIRE)-Otsuka Precision Health, Inc. (OPH) and Click Therapeutics, Inc., (Click) announce today the commercial launch of Rejoyn(TM).

Hit Consultant
May 22nd, 2024
Click Therapeutics Acquires Better Therapeutics, Expands Into Obesity And Cardiometabolic Disease

What You Should Know:– Click Therapeutics, a leader in prescription digital therapeutics (DTx), announced today the acquisition of key assets from Better Therapeutics.– Click’s expansion into cardiometabolic disease follows successful DTx development efforts in other areas, including migraine prevention, depression, schizophrenia, and opioid use disorder.Strengthening the DTx PipelineThe acquisition includes several key assets from Better Therapeutics:AspyreRx (BT-001): The first FDA-authorized DTx for type 2 diabetes.The first FDA-authorized DTx for type 2 diabetes. BT-004: A DTx with FDA Breakthrough Device Designation for treating metabolic dysfunction-associated steatohepatitis (MASH).A DTx with FDA Breakthrough Device Designation for treating metabolic dysfunction-associated steatohepatitis (MASH). BT-002: A DTx designed to reduce blood pressure in patients with hypertension.A DTx designed to reduce blood pressure in patients with hypertension. BT-003: A DTx focused on lowering LDL cholesterol in patients with hyperlipidemia.The strategic acquisition significantly expands Click’s DTx portfolio, complementing their existing offerings in psychiatry, CNS, and pain management. It also strengthens their position in the rapidly growing market for obesity and cardiometabolic disease treatments.A Personalized Approach to Weight ManagementClick’s existing DTx solutions focus on psychiatry, CNS, and pain disorders. By integrating Better Therapeutics’ assets, Click gains immediate traction in the rapidly growing cardiometabolic space, complementing their current offerings.Click emphasizes the importance of personalized treatment plans for obesity, a complex chronic disease

Hit Consultant
May 22nd, 2024
Click Therapeutics Acquires Better Therapeutics, Expands into Obesity and Cardiometabolic Disease

- Click Therapeutics, a leader in prescription digital therapeutics (DTx), announced today the acquisition of key assets from Better Therapeutics.